A top-notch US-based drug-maker Pfizer Inc. (NYSE:PFE) has cut on its yearly revenues and next-yearly profit forecast. The company has put all its blame on a stronger dollar and higher exchange ratio.
A Quarterly Review
In Q12015, the company notched up substantial profits, better than is potentially expected and anticipated. There has been a widespread demand for cancer drugs and vaccines manufactured and patented by PFE. In the last year, the pharmaceutical company got 60% revenue from pan-globe sales, primarily outside the US. Hence, on the premises of stronger extents of dollar value, the company has cut down its forecast from $44.5-$46.5 billion to a limit of $44-$46 billion.
Numbers’ Games
Though the numbers are a bit low than the previously expected forecast, yet the fact is when is such a negative vibe lingering among the PFE authorities. The think tank chose to reduce its entire yearly revenue, though by a meek margin.
Pfizer Inc. (NYSE:PFE) has joined myriad of companies that have cut their forecast earlier in the month. The US dollar has lately gained 9% against a plethora of foreign currencies in the first quarter, after soaring 13% in FY2014. In the quarter that came to a close lately, the company has garnered net profits surpassing $2.38 billion, at a valuation of approximately 38 cents for each share. In a YoY basis, the company had garnered better gains in the last quarter, in comparison to the same profile, even a year back. In 2014, the company garnered net profits of $2.33 billion, valued at 36 cents each year.
Beating the estimates by a number of analysts, Pfizer earned 51 cents for each share, in comparison to the net estimate ranging to 49 cents by Thomson Reuters Corporation (USA) (NYSE:TRI). Despite stock indices falling, the company has fared the charts with profitability.
